Literature DB >> 25351501

The clinical course of recurrent respiratory papillomatosis after the use of cidofovir is influenced by multiple factors.

Michel R M San Giorgi1, Robin E A Tjon Pian Gi, Frederik G Dikkers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25351501     DOI： 10.1007/s00405-014-3366-y

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN： 0937-4477            Impact factor:   2.503


× No keyword cloud information.
  4 in total

1.  Treatment of recurrent respiratory papillomatosis with microsurgery in combination with intralesional cidofovir--a prospective study.

Authors:  Frederik G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-11-22       Impact factor: 2.503

2.  Clinical course of recurrent respiratory papillomatosis: comparison between aggressiveness of human papillomavirus-6 and human papillomavirus-11.

Authors:  Robin E A Tjon Pian Gi; Michel R M San Giorgi; Lorian Slagter-Menkema; Bettien M van Hemel; Bernard F A M van der Laan; Edwin R van den Heuvel; Frederik G Dikkers; Ed M D Schuuring
Journal:  Head Neck       Date:  2014-09-12       Impact factor: 3.147

3.  Use of cidofovir in HPV patients with recurrent respiratory papillomatosis.

Authors:  M Grasso; M Remacle; V Bachy; S Van Der Vorst; G Lawson
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-23       Impact factor: 2.503

4.  Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients.

Authors:  R E A Tjon Pian Gi; T Ilmarinen; E R van den Heuvel; L M Aaltonen; J Andersen; J W Brunings; M Chirila; A Dietz; F Ferran Vilà; G Friedrich; H H W de Gier; W Golusinski; M Graupp; A Hantzakos; R Horcasitas; J Jackowska; J C Koelmel; G Lawson; F Lindner; M Remacle; C Sittel; V Weichbold; M Wierzbicka; F G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-03       Impact factor: 2.503
  4 in total
  2 in total

1.  Response to letter to Editor: "The clinical course of recurrent respiratory papillomatosis after the use of cidofovir is influenced by multiple factors" by Michel R. M. San Giorgi et al.

Authors:  M Grasso; M Remacle; V Bachy; S Van Der Vorst; G Lawson
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-09-21       Impact factor: 2.503

2.  Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis.

Authors:  Robin E A Tjon Pian Gi; Michel R M San Giorgi; Michael Pawlita; Angelika Michel; Bettien M van Hemel; Ed M D Schuuring; Edwin R van den Heuvel; Bernard F A M van der Laan; Frederik G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-05-17       Impact factor: 2.503
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.